Verition Fund Management
CBIO

Verition Fund Management’s Crescent Biopharma CBIO Stock Holding History

Verition Fund Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,624
Closed -$487K – 3092
2024
Q1 		$487K Buy
+1,624
New +$485K ﹤0.01% 2019

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Verition Fund Management's CBIO Position: Q2 2024 in Review

Verition Fund Management sold out of Crescent Biopharma (CBIO) in Q2 2024, closing a stake of 1,624 shares — an estimated $487K sold.

Verition Fund Management first reported a position in CBIO in Q1 2024 and held it in 1 quarter. The position peaked at $487K in Q1 2024. 35 funds tracked by Wall St. Rank hold CBIO as of Q2 2024.

  • Verition Fund Management reported no remaining Crescent Biopharma position as of Q2 2024 after selling out during the quarter.
  • Verition Fund Management sold 1,624 Crescent Biopharma shares in Q2 2024, an estimated $487K.
  • Verition Fund Management first reported a position in Crescent Biopharma in Q1 2024 and held it in 1 quarter.
  • Verition Fund Management's Crescent Biopharma position peaked at $487K in Q1 2024.
  • 35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2024.

Based on Verition Fund Management's 13F filing for Q2 2024, filed 14 Aug 2024.